Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data
Authors:
Open Access
- 24 March 2023
- journal article
- review article
- Published by Elsevier in Asia-Pacific Journal of Ophthalmology
- Vol. 12 (2) , 168-183
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services researchGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Stability engineering of scFvs for the development of bispecific and multivalent antibodiesProtein Engineering, Design and Selection, 2010
- Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal AntibodiesJournal of Biological Chemistry, 2010
- Age-related macular degeneration: diagnosis and managementBritish Medical Bulletin, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004